Go to Top


At your service

Bluebee’s genome analytics platform combines best-in-class tools and components to enable efficient pipeline processing. Our innovative hybrid-core architecture demonstrates impressive performance gains, at substantially lower cost.

Read more

Stay focused

Rather than spending scant budgets on capital intensive investments in hardware and infrastructure support headcount, Bluebee’s cloud based solutions allow you to focus efforts and your best people for the right cause: better analytics.

Read more

Flexible solutions

We all know there is no "one size fits all". Pipelines need to be specifically designed for the use case and all associated variables. But that does not mean you need a bespoke solution. Bluebee offers a flexible solution based on configurable and editable pipelines.

Read more

Full transparancy

At Bluebee we use generally accepted and verifiable algorithms. What makes us unique is the way we run them on high performance computing infrastructure, significantly increasing processing speed. We gain speed through acceleration, not by adapting the science.

Read more


OpenPOWER Personalized Medicine Work Group

We are proud to announce that Bluebee co-founder Dr. Zaid Al-Ars has been elected as chairman of the newly chartered OpenPOWER workgroup named the Personalized Medicine Work Group. The workgroup brings together technology leaders in the field and consolidates the efforts to create effective genomics computational solutions. Founding members of the workgroup are IBM, Altera Corporation, Nallatech and next generation sequencing data analysis provider Bluebee.Read More

Bluebee Bronze Sponsor at a Cambridge Rare Disease Event

Bluebee is proud to be a Bronze Sponsor of the Cambridge Rare Disease Summit, held on Monday 14th September at the renown Cambridge Judge Business School, UK.

The Cambridge Rare Disease Network (CRDN) is bringing together 150 key stake holders to debate on how best to address the huge social and therapeutic unmet needs in the rare disease field.

Rare disorders are of focus of the £300-million initiative from National

Read More